Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110585632 | 11058563 | 2 | F | 20160907 | 20150423 | 20160908 | EXP | CA-ROCHE-1566321 | ROCHE | 0.00 | M | Y | 0.00000 | 20160908 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110585632 | 11058563 | 1 | PS | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Subcutaneous | U | 103964 | 180 | UG | /wk | |||||||
| 110585632 | 11058563 | 2 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | U | 21511 | TABLET | QD | ||||||||
| 110585632 | 11058563 | 3 | SS | VICTRELIS | BOCEPREVIR | 1 | Oral | U | 0 | 800 | MG | CAPSULE | TID | ||||||
| 110585632 | 11058563 | 4 | C | OXAZEPAM. | OXAZEPAM | 1 | Unknown | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 110585632 | 11058563 | 1 | Chronic hepatitis C |
| 110585632 | 11058563 | 2 | Chronic hepatitis C |
| 110585632 | 11058563 | 3 | Chronic hepatitis C |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 110585632 | 11058563 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 110585632 | 11058563 | Dyspnoea | |
| 110585632 | 11058563 | Rash | |
| 110585632 | 11058563 | Testicular pain |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |